Majedie Investments NAV Return Tops CPI+4% Target as DCC Bid and Brown Advisory Deal Reshape Quarter26/08/2026
Revolution Medicines Wins FDA Pancreatic Cancer Drug ApprovalBy Martin Holloway26/08/2026 The FDA’s pancreatic cancer drug approval for Revolution Medicines’ daraxonrasib lands months early, but the stock barely moved. Here’s why.
Majedie Investments NAV Return Tops CPI+4% Target as DCC Bid and Brown Advisory Deal Reshape Quarter26/08/2026
